Pfizer (PFE) Asset Writedowns and Impairment (2009 - 2026)

Pfizer (PFE) has reported Asset Writedowns and Impairment for 17 consecutive years, with $4.4 billion the latest figure, recorded in Q4 2025.

• In Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $4.4 billion; the TTM figure through Mar 2026 stood at $4.8 billion (up 401.48% YoY), while the FY2025 annual figure was $5.3 billion, up 59.7% from the prior year.
• Asset Writedowns and Impairment climbed to $4.4 billion in Q4 2025 per PFE's latest filing, from $260.0 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $4.4 billion in Q4 2025 and bottomed at $24.0 million in Q2 2021.
• Historically, Asset Writedowns and Impairment has averaged $500.7 million across 5 years, with a median of $224.0 million in 2025.
• Annual changes were most pronounced in 2021 — Asset Writedowns and Impairment sank 89.67% — and 2023, when it jumped 770.97%.
• Pfizer's Asset Writedowns and Impairment stood at $93.0 million in 2021, then slumped by 66.67% to $31.0 million in 2022, then surged by 1035.48% to $352.0 million in 2023, then retreated by 0.85% to $349.0 million in 2024, then jumped by 1162.46% to $4.4 billion in 2025.
• Business Quant data shows PFE's Asset Writedowns and Impairment at $4.4 billion in Q4 2025, $260.0 million in Q3 2025, and $93.0 million in Q2 2025.